ΔNp73异型定义了一个类似TP53突变的急性髓性白血病低风险亚组

Diego A Pereira-Martins1, Cesar Ortiz2, Isabel Weinhäuser3

  • 1Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Department of Medical Imaging, Haematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil; Center for Cell Based Therapy, São Paulo Research Foundation, Ribeirão Preto, SP, Brazil; Hematology Division, LIM31, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil.

Cell reports. Medicine
|January 9, 2026
PubMed
概括

一部分急性髓性白血病 (AML) 患者对治疗有抗性,过度表达瘤原体 ΔNp73. 使用guanfacine抑制CEBPA可降低ΔNp73,恢复药物敏感性并改善AML的治疗结果.